Sandusky, OH – August 14, 2020 – — PAO Group, Inc. (OTC PINK: PAOG) today announced the company is aggressively pursuing international research partnerships to advance its cannabis respiratory treatment development.
The company recently revealed research partnership developments in Puerto Rico where Congresswoman Jenniffer González Colón and Florida Senator Marco Rubio recently introduced legislation to position Puerto Rico as a global production center of medical equipment and drugs.
Israel is recognized as one of the leading cannabis research centers in the world. Parallel to PAOG’s own research on its proprietary cannabis extract for the treatment of COVID-19, a study in Israel was recently released with findings that turpentines in cannabis showed efficacy in treating COVID-19,
PAOG recently acquired the proprietary formulations derived from a patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The formulation tradename is RespRx.
The RespRx CBD Biopharma treatment targets multiple respiratory-related diseases to include COPD and COVID-19.
A paper on the results of the study was published and well-received, given the potential impact on this large market. WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.